Literature DB >> 8102105

ErbA: tumor suppressor turned oncogene?

K Damm1.   

Abstract

Cancer has been commonly linked to aberrant proliferation and a failure of the transformed cells to differentiate. Activated proto-oncogenes are thought to provide continuous proliferation signals that enhance the growth of these cells. Conversely, cellular transformation may also be achieved by the inactivation of genes whose normal function is to constrain cell growth by either suppressing proliferation or inducing differentiation. Such an inactivation could result from dominant-negative mutations, leading to the expression of abnormal proteins that inhibit the function of their normal counterparts. A prototype example is the v-erbA oncogene of the avian erythroblastosis virus (AEV), which antagonizes the transcriptional regulatory function of the chicken c-ErbA/thyroid hormone receptors (c-ErbA/TR) and the structurally related retinoic acid receptors (RARs). The result of this inhibition is a loss of hormone responsiveness and hormone-induced differentiation. Here we have a parallel to the tumor suppressor gene where it is also a loss of function that induces the transformation process. In this way, the normal, hormone-activated c-ErbA/TRs and RARs act as growth suppressors because the resulting differentiated cells irreversibly lose proliferative potential. In this article, the properties of v-ErbA will be discussed in the context of c-ErbA/thyroid hormone and retinoic acid receptor function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102105     DOI: 10.1096/fasebj.7.10.8102105

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  3 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Elevated expression of thyroid hormone receptor alpha 2 (c-erb A- alpha 2) in nasopharyngeal carcinoma.

Authors:  J W Lee; C L Chen; B T Juang; J Y Chen; C S Yang; S L Doong
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

3.  Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.

Authors:  Min Shi; Weizhen Huang; Li Lin; Dayong Zheng; Qiang Zuo; Lin Wang; Nina Wang; Yajun Wu; Yulin Liao; Wangjun Liao
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.